Introduction
Ulcerative proctitis (UP) fails to respond to first-line treatment in one third of patients, and evidence supporting the use of advanced therapies in this setting is scarce. Filgotinib, a selective Janus kinase (JAK) inhibitor, has demonstrated efficacy in ulcerative colitis; however, data in isolated UP remain limited.
Aims & Methods
The study aimed to evaluate the effectiveness and safety of filgotinib in patients with active UP. This retrospective multicentre study included adult patients with active UP (partial Mayo score > 2 and/or endoscopic activity defined by a Mayo endoscopic subscore ≥2 or a UCEIS >4) who initiated filgotinib between March 2022 and March 2025. The primary endpoint was steroid-free clinical remission (SFCR) at week 8 (partial Mayo ≤ 2, no subscore > 1). Secondary endpoints included clinical response (defined as a decrease of at least 30% of the partial Mayo score from baseline), improvement in fecal urgency and anal incontinence between baseline and week 8, treatment persistence at 12 months, and safety.
Results
Twenty-eight patients were included (64% female; median age 43 years (IQR: 39-48), median disease duration 6 years (IQR:2.5-11.5)) from 10 French and Belgian GETAID centers. All patients had prior exposure to advanced therapies: anti-TNF agents (79%), vedolizumab (82%), ustekinumab (43%), and JAK inhibitors (18%; including three patients treated with upadacitinib, four with tofacitinib, and two with both). Thirteen patients (46%) had been exposed to at least three advanced therapies. Three patients (11%) were receiving concomitant oral corticosteroids, and four (14%) were receiving topical therapies. At baseline, the median partial Mayo score was 6 (IQR: 5-6) and 88% (n=22/25) of patients had active endoscopic proctitis (Mayo endoscopic sub score ≥2 or a UCEIS >4). Median fecal calprotectin level was 899 µg/g (n=13), and C-reactive protein (CRP) was elevated (>5 mg/L) in 30% (7/23). At week 8 (IQR:6-10), steroid-free clinical response and SFCR were both achieved in 64% of patients (18/28). Between baseline and week 8, fecal urgency decreased from 54% (15/28) to 32% (9/28) (p= 0.03), and anal incontinence from 11% (3/28) to 4% (1/28) (p= 0.3). Among patients with endoscopic reassessment (n=11), endoscopic response was observed in 64% of patients and remission in 18% after a median follow-up of 12 weeks (IQR: 8-17). No predictors of SFCR were identified. At a second assessment (median follow-up: 8 months [IQR 6–11], n=20), 14 (70%) were in SFCR. Persistence of filgotinib was 77% at both 6 and 12 months. At one year, disease extension occurred in three patients. No adverse events or colectomies were reported.
Conclusion
This study represents the largest real-world multicentre cohort of patients with active refractory UP treated with filgotinib. Filgotinib demonstrated rapid clinical effectiveness, sustained remission, and a favorable safety profile, together with meaningful improvement in debilitating symptoms such as fecal urgency and incontinence. These findings support its role as a therapeutic option in this refractory UP.
Disclosure
Funding : This study was supported by Alfasigma, which did not participate in study design, patient recruitment, data collection or analysis, nor abstract writing.
Apolline LOIEZ declare no conflict of interest
Anneline Cremer has received consulting/speakers fees from AbbVie, Takeda, Alfasigma, Johnson & Johnson, Celltrion, Galapagos, Eli Lilly, Pfizer.
Catherine Reenaers has received research grants from Ferring, Janssen, Takeda, Fresenius, and Biogen and personal fees from Ferring, Janssen, Takeda, Fresenius, AbbVie, Galapagos, Pfizer, Celltrion, Thermo Fisher, Bristol-Myers Squibb (BMS), and Lilly.
Nicolas Richard has received lecture/consultant fees from AbbVie, Amgen, Celltrion, Ferring, Johnson & Johnson, Lilly, Sandoz and Takeda
Carmen Stefanescu received consulting fees from AbbVie, Amgen, Ferring, Pfizer, Janssen, MSD, and Takeda
Bénédicte Caron has received lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Lilly, Nordic Pharma, Pfizer, Sandoz, Takeda.
Romain Altwegg has received consulting/advisory board fees from AbbVie, Celltrion, Ferring, Johnson and Johnson, Amgen, Takeda, Pfizer, Biogen Sandoz
Aurélien Amiot received consulting fees from Abbvie, Hospira, Janssen, Tillotts, Pfizer, Takeda, Gilead and Biocodex as well as lecture fees and travel accommodations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Pfizer, Biogen, Amgen, Fresenius Kabi, Ferring, Tillotts, Takeda and MSD. He also received advisory board fees from Gilead, Tillotts, Takeda and Abbvie.
Morgane Amil has received advisory board and/or speaker fees from AbbVie, MSD
Anthony Buisson declares: Consulting fees from Abbvie, Amgen, Arena, Biogen, Celltrion Healthcare, CTMA, Galapagos/AlfaSigma, GutyCare/Resilience Janssen, Lilly, MSD, Nexbiome, Pfizer, Roche, Sandoz, Takeda and Tillotts. Lecture fees from Abbvie, Amgen, Biogen, Celltrion Healthcare Galapagos/AlfaSigma, Janssen, Lilly, Mayoli-Spindler, MSD, Nordic Pharma, Norgine, Pfizer, Roche, Takeda, Tillotts and Vifor Pharma. Research grant from Abbvie, Celltrion Healthcare, Janssen, Lessaffre, Lilly, Pfizer, Sandoz and Takeda
Nicolas Duveau has received consulting/advisory board fees from AbbVie, Janssen, Amgen, Takeda, Pfizer, Boston scientific, Cook medical.
Pauline WILS has received consulting/advisory board fees from AbbVie, Celltrion, Ferring, Johnson and Johnson, Amgen, Takeda, Pfizer.